Loading stock data…
Insulet Corporation (PODD)
$142.28-5.20 (-3.53%)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $142.28 with a market capitalization of $9.9B. Wall Street consensus targets $171.91 (22 analysts), implying a +20.8% move over the next 12 months. The stock is currently near its 52-week low of $126.40, remaining 32.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $801.70M↑ | $761.70M↓ | $783.80M↑ | $706.30M↑ | $649.10M |
| Gross Profit | $562.60M↑ | $529.10M↓ | $568.60M↑ | $510.10M↑ | $452.20M |
| Operating Income | $129.70M↑ | $122.20M↓ | $146.30M↑ | $117.70M↓ | $121.10M |
| Net Income | $95.00M↑ | $91.10M↓ | $101.60M↑ | $87.60M↑ | $22.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.45
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.52%
Volume
Today's trading volume
2.22M
Recent News
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.
Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds
Insulet stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples currently point to the shares trading below what those models suggest, while the broader valuation score still comes through as a mixed signal rather than a clear bargain. The share price is down 57.0% over the past year, which puts recent trading well below where many investors may have entered the stock. Future adoption of Insulet's...
Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks?
Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a share price of US$148.38, Insulet has seen short term resilience with a 7 day share price return of 3.73%. However, the 30 day share price return is down 10.26% and the 1 year total shareholder return has declined 56.98%, which points to fading momentum as...
MiniMed submits new patch pump for FDA clearance
The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.